New Analysis Finds Suicidal Thoughts Signal With Semaglutide

 
• By Elizabeth Cairns
  
Generate a summary of this article
Listen to this article
Beta

Database review contradicts earlier findings with Novo Nordisk’s blockbuster incretin, but its small size and flawed design mean its commercial implications will be limited.    

Pair of hands holding semaglutide injection pen
• Source: Shutterstock

Four months after a European review of clinical data concluded that there was no association between GLP-1-based drugs and suicidal and self-injurious thoughts and actions, a review of a World Health Organization (WHO) database has come to a different conclusion.

Key Takeaways

  • An analysis of a World Health Organization adverse events database suggests that the risk of suicidal thoughts may be higher with semaglutide than with other drugs.

The analysis, published in JAMA 20 August, found evidence of a higher rate of suicidal thoughts among patients taking semaglutide,...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Business

Test Roche Head Of Pharma Strategy Karsten Jung On Rebuilding The Portfolio

 
• By Jessica Merrill

The Swiss pharma company is rebalancing the portfolio, emphasizing best-in-class drugs and moving into new areas like cardiovascular and metabolic disease.

Quick Listen: Scrip’s Five Must-Know Things

 
• By Reed Miller

In this week's episode: Trump’s UK drug pricing win; Novo explains semaglutide Alzheimer's rationale; J&J and Novartis on this year’s biggest M&A deals; a look at the mixed performance of CAR-Ts; and Akeso’s goals beyond ivonescimab.

Article Without An Author Listed

Here is a short description.

Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]

Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.

More from Scrip

EHA: Lilly’s Jaypirca Posts First Phase III Triplet Win In CLL While BTK Degraders Advance - Clone

Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.

Top 10 Drugs Q1 2026: New Sheriff In Town As Mounjaro Unseats Keytruda

Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains